Bristol-Myers keen to clear out of infection control:
This article was originally published in Clinica
Executive Summary
Bristol-Myers Squibb wants to sell the infection and contamination control businesses which are part of its ConvaTec division. The sectors up for sale were part of Bristol-Myers' acquisition of Calgon Vestal Laboratories last year.